Back
Target discovery
Our target discovery platform uses human primary cells to model diseases of interest in combination with functional genomics. We introduce cDNA (FLeXSelect) or shRNA (SilenceSelect) into cells using our collections of adenoviruses in order to study the roles of individual genes in disease processes. Advanced readouts, such as high content screening, are then used to identify the genes that have an effect on the disease. After further validation assays, these targets form the basis for the development of new drugs.
Our unique approach combines human primary cell assays with high throughput adenoviral technology, supported by state-of-the-art monitoring equipment.
If you would like to know more about our services, discuss custom assays, specific research, or get a quote, please contact us.
Our target discovery process
- Over ten years’ experience in target discovery; we were the first company to use human primary cells and shRNA technology in high-throughput screening for target discovery
- Proprietary innovative adenoviral and RNA interference (RNAi) technology
- Efficient introduction of cDNA and shRNA into a wide range of primary cells – including stem cells
- Prolonged expression of cDNA and shRNA allows complex processes to be studied, including cellular differentiation
In this section:
Print to HTML
Print as PDF
Send to a friend